In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 799-801

  Kaatz, Glenn W ^a   Seo, Susan M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPEREZOLID; LINEZOLID; NAFCILLIN; OXAZOLIDINONE DERIVATIVE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 0029976183     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.799     Document Type: Article

References (13)

1. Ashtekar, D. R., R. Costa-Periera, T. Shrinivasan, R. Iyyer, N. Vishvanathan, and W. Rittel. 1991. Oxazolidmones, a new class of synthetic antituberculosis agent In vitro and in vivo activities of DuP 721 against Mycobacterium tuberculosis. Diagn Microbiol. Infect. Dis. 14:465-471.
2. Barry, A. L. 1988 In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents Antimicrob Agents Chemother 32:150-152
3. Brumfitt, W., and J. M. T. Hamilton-Miller. 1988. In-vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones. J. Antimicrob. Chemother 21:711-720.
4. Brumfitt, W., and J. M. T. Hamilton-Miller. 1992. Antibacterial oxazolidinones. In vitro activity of a new analogue, E3709. Diagn. Microbiol. Infect Dis. 15:621-625.
5. Bryson, V., and W. Szybalski. 1952. Microbial selection. Science 116:45-51
6. Daly, J. S., G. M. Eliopolous, E. Reiszner, and R. C. Moellering. 1988. Activity and mechanism of action of DuP 105 and DuP 721. new oxazolidinone compounds J Antimicrob. Chemother. 21:721-730
7. Daly, J. S., G. M. Eliopolous, S. Willey, and R. C. Moellering. 1988. Mechanism of action and in vitro activities of S-6123, a new oxazolidinone compound. Antimicrob. Agents Chemother. 32:1341-1346.
8. Eustice, D. C., P. A. Feldman, I. Zajac, and A. M. Slee. 1988. Mechanism of action of Dup 721: inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother. 32:1218-1222.
9. National Committee for Clinical Laboratory Standards. 1990. Approved standard M7-A2 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed. National Committee for Clinical Laboratory Standards, Villanova, Pa.
10. Neu, H. C., A. Novelli, G. Saha, and N.-X. Chin. 1988. In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105. Antimicrob. Agents Chemother 32:580-583
11. Pawsey, S. D., J. D. Harry, and D. J. Stalker. 1995. 1st administration of a new oxazolidinone antibiotic (U-100592) to man, abstr. F225, p. 152. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Slee, A. M., M. A. Wuonola, R. J. McRipley, I. Zajac, M. J. Zawanda, P. T. Bartholomew, W. A. Gragory, and M. Forbes. 1987 Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother. 31:1791-1797
13. Stratton, C. W., and R. C. Cooksey. 1991. Susceptibility tests: special tests, p. 1153-1165. In A. Balows, W. J. Hausler, Jr., K. L. Hermann, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.